Navigation Links
MedArt® 435

ProductsMedArt® 435
Company Asah Medico A/S
Item MedArt® 435
Features 
  • The first 810 nm, 90 W Diode laser
  • Hair reduction, vascular lesions, leg vein
  • First diode based laser available with integrated scanner and skin cooling system
  • Continuous or pulsed mode
  • Portable, compact, reliable and requiring very little maintenance
  • Pulse width: 50 to 1000 milliseconds
  • Scanner option
    • Description The MedArt® 435 is a full system for hair removal, with scanner and skin cooling system which makes up a complete hair reduction system. The 90W laser generates enough power to ensure sufficient heating of the hair bulb and bugle. To ease and optimise treament, the laser beam is distributed to the tissue through the MedArt® 413 scanner. The laser beam is delivered through a thin 1000 m flexible fiber, which gives the operator full freedom of movement during treatment. Easy, safe and unclomplicated fiber connection is provided by the specially developed "Quick Safe Connect" (Patent Pending) System. Field selection buttons and toggle wheel make the setting of treatment parameters fast and easy. Alpha-numeric display with "What You See Is What You Get" for easy reading. The built-in powermeter is designed for accurate measuring of laser output as well as scanner output. The fiber can be fitted with various optical fiber tips with spot diameters of 1.2 mm, 2.5 mm and 4.0 mm. The 1.2 mm and 2.5 mm tip are particularly well suited for vascular lesions while the 4 mm tip is well suited for hair removal in areas difficult to reach by scanner. The tips can be fitted to the fiber without the use of any tools.
    Info Asah Medico A/S
    Customer Service: +45 3634 2300

    Related medicine products :

    1. MedArt® 426
    TAG: MedArt reg
    Breaking Medicine Technology:ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Lack of happiness hormone serotonin in the brain causes impaired maternal behavior in mice 8972 1Energy saving method checks refrigerant level in air conditioners 8970 1Energy saving method checks refrigerant level in air conditioners 8970 2How to text message and avoid pain 8968 1How to text message and avoid pain 8968 2